MMNBX | VIVIX | MMNBX / VIVIX | |
Total Expense Ratio | 0.74 | 0.04 | 1,850% |
Annual Report Gross Expense Ratio | 0.74 | 0.04 | 1,850% |
Fund Existence | 2 years | 27 years | - |
Gain YTD | 7.106 | 5.609 | 127% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 100000 | 5000000 | 2% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 338M | 189B | 0% |
Annual Yield % from dividends | 1.73 | 2.19 | 79% |
Returns for 1 year | -15.88 | 11.41 | -139% |
Returns for 3 years | N/A | 34.40 | - |
Returns for 5 years | N/A | 79.11 | - |
Returns for 10 years | N/A | 114.45 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GAFFX | 82.92 | 0.81 | +0.99% |
American Funds Growth Fund of Amer F3 | |||
DCEMX | 13.94 | N/A | N/A |
Dunham Emerging Markets Stock C | |||
IIIIX | 13.08 | N/A | N/A |
Voya International Index Port I | |||
WFTCX | 5.16 | N/A | N/A |
Allspring Innovation Fund - Class C | |||
JFNIX | 66.23 | N/A | N/A |
Janus Henderson Global Life Sciences I |